Dechra Pharmaceuticals Management

Management criteria checks 4/4

Dechra Pharmaceuticals' CEO is Ian Page, appointed in Nov 2001, has a tenure of 21.42 years. total yearly compensation is £2.07M, comprised of 28.8% salary and 71.2% bonuses, including company stock and options. directly owns 0.36% of the company’s shares, worth MX$338.86M. The average tenure of the management team and the board of directors is 5.8 years and 4.2 years respectively.

Key information

Ian Page

Chief executive officer

UK£2.1m

Total compensation

CEO salary percentage	28.8%
CEO tenure	21.4yrs
CEO ownership	0.4%
Management average tenure	5.8yrs
Board average tenure	4.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ian Page's remuneration changed compared to Dechra Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2022	n/a	n/a	UK£40m
Sep 30 2022	n/a	n/a	UK£49m
Jun 30 2022	UK£2m	UK£597k	UK£58m
Mar 31 2022	n/a	n/a	UK£66m
Dec 31 2021	n/a	n/a	UK£73m
Sep 30 2021	n/a	n/a	UK£64m
Jun 30 2021	UK£3m	UK£551k	UK£56m
Mar 31 2021	n/a	n/a	UK£50m
Dec 31 2020	n/a	n/a	UK£44m
Sep 30 2020	n/a	n/a	UK£39m
Jun 30 2020	UK£2m	UK£517k	UK£34m
Mar 31 2020	n/a	n/a	UK£31m
Dec 31 2019	n/a	n/a	UK£29m
Sep 30 2019	n/a	n/a	UK£30m
Jun 30 2019	UK£3m	UK£500k	UK£31m
Mar 31 2019	n/a	n/a	UK£28m
Dec 31 2018	n/a	n/a	UK£25m
Sep 30 2018	n/a	n/a	UK£30m
Jun 30 2018	UK£3m	UK£500k	UK£36m
Mar 31 2018	n/a	n/a	UK£40m
Dec 31 2017	n/a	n/a	UK£43m
Sep 30 2017	n/a	n/a	UK£35m
Jun 30 2017	UK£3m	UK£490k	UK£26m
Mar 31 2017	n/a	n/a	UK£19m
Dec 31 2016	n/a	n/a	UK£11m
Sep 30 2016	n/a	n/a	UK£12m
Jun 30 2016	UK£2m	UK£440k	UK£13m

Compensation vs Market: Ian's total compensation ($USD2.58M) is about average for companies of similar size in the MX market ($USD2.75M).

Compensation vs Earnings: Ian's compensation has been consistent with company performance over the past year.

CEO

Ian Page (61 yo)

21.4yrs

Tenure

UK£2,073,000

Compensation

Mr. Ian D. Page has been the Chief Executive Officer and Managing Director of Dechra Pharmaceuticals Plc since November 2001 and 1998 respectively and also serves as its Executive Director since June 13, 1...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ian Page	CEO, MD & Executive Director	21.4yrs	UK£2.07m	0.36% MX$ 338.9m
Paul Sandland	CFO & Executive Director	4yrs	UK£932.00k	0.010% MX$ 9.8m
Anthony Griffin	MD of Dechra Veterinary Products for Europe & Executive Director	10.9yrs	UK£856.00k	0.033% MX$ 31.0m
Patrick Meeus	Group Scientific Officer	less than a year	no data	no data
Katy Clough	Group HR Director	no data	no data	no data
Mike Eldred	President of North America	no data	no data	no data
Melanie Hall	Company Secretary	5.8yrs	no data	no data

5.8yrs

Average Tenure

55.5yo

Average Age

Experienced Management: DPH N's management team is seasoned and experienced (5.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ian Page	CEO, MD & Executive Director	25.8yrs	UK£2.07m	0.36% MX$ 338.9m
Paul Sandland	CFO & Executive Director	3.5yrs	UK£932.00k	0.010% MX$ 9.8m
Anthony Griffin	MD of Dechra Veterinary Products for Europe & Executive Director	10.4yrs	UK£856.00k	0.033% MX$ 31.0m
Ishbel Jean Macpherson	Independent Non-Executive Director	10.2yrs	UK£83.00k	0.0059% MX$ 5.6m
Geeta Gopalan	Non-Executive Director	less than a year	no data	no data
Lawson MacArtney	Senior Independent Director	6.3yrs	UK£78.00k	0.0052% MX$ 4.9m
Alison Platt	Non-Executive Chairman	3.1yrs	UK£132.00k	0.0033% MX$ 3.1m
Lisa Morrison	Designated Non-Executive Director	4.2yrs	UK£72.00k	0.0012% MX$ 1.2m
John Shipsey	Non-Executive Director	less than a year	UK£5.00k	0.00053% MX$ 505.4k

4.2yrs

Average Tenure

59yo

Average Age

Experienced Board: DPH N's board of directors are considered experienced (4.2 years average tenure).

Dechra Pharmaceuticals Management

Management criteria checks 4/4

Key information

Recent management updates

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Less than half of directors are independent

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

Less than half of directors are independent

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Less than half of directors are independent

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Announces Executive Changes

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Investor sentiment improved over the past week

Non-Executive Chairman recently bought Mex$2.6m worth of stock

Investor sentiment improved over the past week

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Investor sentiment deteriorated over the past week

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Less than half of directors are independent

Upcoming dividend of UK£0.29 per share

Less than half of directors are independent

Non-Executive Director recently bought Mex$178k worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Less than half of directors are independent

Board Member recently sold Mex$27m worth of stock

Non-Executive Director recently bought Mex$587k worth of stock

Non-Executive Director recently bought Mex$587k worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

CEO, MD & Executive Director recently sold Mex$279m worth of stock

Dechra Pharmaceuticals PLC Launches Mirataz

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

Non-Executive Director recently bought Mex$712k worth of stock

Independent Non Executive Director recently sold Mex$3.5m worth of stock

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age